Adaptive Biotechnologies Corp.
- ADPT · Nasdaq
- Biological Products, (No Diagnostic Substances)
- Seattle, WA
- 624 employees
- CIK 0001478320
Updated from SEC filings through
Top things to know
Executives
-
Chad Robins Chief executive officer and co-founder of Adaptive Biotechnologies 8-K, 2026-11-04 - Chad M. Robins CEO and Chairman 4, 2026-08-19
- Kyle Piskel Chief Financial Officer 4, 2026-05-20
- Francis Lo Chief People Officer 4, 2026-09-18
-
Susan Bobulsky Chief Commercial Officer, MRD 4, 2026-09-17 - Harlan S. Robins Chief Scientific Officer 4, 2026-07-23
What leadership is saying
“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Adaptive Biotechnologies Corp is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Seattle, WA. It trades as ADPT on Nasdaq. Revenue was $277M in the fiscal year ending December 31, 2025, +54.8% from the year before. It reported about 624 employees. Chad Robins is Chief executive officer and co-founder of Adaptive Biotechnologies.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $277M 10-K, 2026-02-26 | $179M 10-K, 2026-02-26 | $170M 10-K, 2026-02-26 | $185M 10-K, 2025-03-03 | $154M 10-K, 2024-02-29 |
| Operating income | -$57.1M 10-K, 2026-02-26 | -$163M 10-K, 2026-02-26 | -$227M 10-K, 2026-02-26 | -$200M 10-K, 2025-03-03 | -$209M 10-K, 2024-02-29 |
| SG&A | $167M 10-K, 2026-02-26 | $158M 10-K, 2026-02-26 | $173M 10-K, 2026-02-26 | $184M 10-K, 2025-03-03 | $170M 10-K, 2024-02-29 |
| Net income | -$59.5M 10-K, 2026-02-26 | -$159M 10-K, 2026-02-26 | -$225M 10-K, 2026-02-26 | -$200M 10-K, 2025-03-03 | -$207M 10-K, 2024-02-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Chad Robins | Chief executive officer and co-founder of Adaptive Biotechnologies | 8-K, 2026-11-04 |
| Chad M. Robins CEO and Co-Founder at Adaptive Biotechnologies Corporation | CEO and Chairman | 4, 2026-08-19 |
| Kyle Piskel | Chief Financial Officer | 4, 2026-05-20 |
| Francis Lo Chief People Officer @ Adaptive Biotechnologies Corp. | Chief People Officer | 4, 2026-09-18 |
| Susan Bobulsky Chief Commercial Officer, MRD at Adaptive Biotechnologies Corp. | Chief Commercial Officer, MRD | 4, 2026-09-17 |
| Harlan S. Robins | Chief Scientific Officer | 4, 2026-07-23 |
| Sharon Benzeno Chief Commercial Officer, Immune Medicine | Chief Commercial Ofc Imm Med | 4, 2026-06-30 |
 Julie Rubinstein | President and COO | 4, 2026-04-29 |
| Harlan Robins, PhD | Named in proxy bio: Chief Scientific Officer | DEF 14A, 2026-04-24 |
| Katey Owen, PhD | Board member (per proxy) bio: Class I director | DEF 14A, 2026-04-24 |
| Peter Neupert | Board member (per proxy) bio: member of our board of directors | DEF 14A, 2026-04-24 |
| Robert Hershberg, PhD, MD | Board member (per proxy) bio: Class I director | DEF 14A, 2026-04-24 |
| Michelle Griffin | a member of our Board of Directors | 10-K, 2026-02-26 |
What Adaptive Biotechnologies Corp does
Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 161.9 million (as of October 30, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $1.4B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 2 (period ending December 31, 2025) | 10-K, February 26, 2026 |
| Latest proxy statement | Meeting June 5, 2026 (filed April 24, 2026) | DEF 14A, April 24, 2026 |
| Auditor | Ernst & Young LLP (Seattle, Washington) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 6, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $954K | Form 4, November 6, 2026 |
| November 3, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $929K | Form 4, November 3, 2026 |
| October 29, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $998K | Form 4, October 29, 2026 |
| October 26, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $897K | Form 4, October 26, 2026 |
| October 21, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $879K | Form 4, October 21, 2026 |
| October 16, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $897K | Form 4, October 16, 2026 |
| October 13, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $920K | Form 4, October 13, 2026 |
| October 8, 2026 | Julie Rubinstein President and COO | Sale | 35,643 | $948K | Form 4, October 8, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-22
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- Item 8.01 Other events
- 8-K filed 2026-06-15
- Item 8.01 Other events
- 8-K filed 2026-06-09
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-12-30
- Item 8.01 Other events
- 8-K filed 2025-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Adaptive Biotechnologies Corp
- What does Adaptive Biotechnologies Corp do?
- In its own words, from Item 1 of its 10-K: "Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities."
- What is Adaptive Biotechnologies Corp's revenue?
- $277M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Adaptive Biotechnologies Corp profitable?
- Adaptive Biotechnologies Corp reported net income of -$59.5M for the fiscal year ending December 31, 2025.
- How many employees does Adaptive Biotechnologies Corp have?
- About 624 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Adaptive Biotechnologies Corp?
- Chad Robins, Chief executive officer and co-founder of Adaptive Biotechnologies, as named in a 8-K filed November 4, 2026.
- Who is the CFO of Adaptive Biotechnologies Corp?
- Kyle Piskel, Chief Financial Officer, as named in a 4 filed May 20, 2026.
- Where is Adaptive Biotechnologies Corp headquartered?
- Seattle, WA.
- What is Adaptive Biotechnologies Corp's stock ticker?
- ADPT on Nasdaq.
- What industry is Adaptive Biotechnologies Corp in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Adaptive Biotechnologies Corp's website?
- adaptivebiotech.com.
- When does Adaptive Biotechnologies Corp report earnings next?
- February 1, 2027. Source: estimate_8k_pattern.
- Is Adaptive Biotechnologies Corp a public company?
- Yes. Adaptive Biotechnologies Corp files with the SEC under CIK 0001478320 and trades as ADPT.
- Who audits Adaptive Biotechnologies Corp?
- Ernst & Young LLP, Seattle, Washington, as named in its latest annual report (10-K).
- How many shares of Adaptive Biotechnologies Corp are outstanding?
- 161.9 million shares as of October 30, 2026, from its 10-Q filed November 4, 2026.
- What is Adaptive Biotechnologies Corp's public float?
- $1.4B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Adaptive Biotechnologies Corp report?
- 2 reportable segments for the period ending December 31, 2025, from its 10-K filed February 26, 2026.
- When is Adaptive Biotechnologies Corp's annual shareholder meeting?
- June 5, 2026, per its proxy statement (DEF 14A) filed April 24, 2026.
- Have Adaptive Biotechnologies Corp insiders traded stock recently?
- Since April 13, 2026, officers and directors reported 38 open-market sales worth about $66.7M and 0 purchases on Forms 4 and 5. The most recent: Julie Rubinstein (President and COO) sold 35,643 shares on November 6, 2026.